Back to Search
Start Over
Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
- Source :
- Cancer Science
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Considering the increasing number of identified driver oncogene alterations, additional genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (NSCLC). Next‐generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. In this retrospective, multicenter study (UMIN ID000039523), we evaluated real‐world clinical data using the Oncomine Dx Target Test Multi‐CDx System (Oncomine DxTT) as a companion diagnostic system. Patients with NSCLC who were tested for a panel of 46 genes using the Oncomine DxTT between June 2019 and January 2020 were eligible for enrollment. Patients from 19 institutions affiliated to the West Japan Oncology Group were recruited. The primary endpoint of the study was the success rate of genetic alteration testing in four driver genes (EGFR, ALK, ROS1, and BRAF) using the Oncomine DxTT. In total, 533 patients were enrolled in the study. The success rate of genetic alteration testing for all four genes was 80.1% (95% CI 76.5%‐83.4%). Surgical resection was associated with the highest success rate (88.0%), which was significantly higher than that for bronchoscopic biopsy (76.8%, P = .005). Multivariate analysis revealed a significant difference for surgical resection alone (P = .006, 95% CI 1.36‐6.18, odds ratio 2.90). Although the success rate of genetic alteration testing immediately after Oncomine DxTT induction was not sufficient in this study, optimizing specimen quantity and quality may improve the use of driver gene testing in clinical settings.<br />The mutation identification success rate for all four genes was 80.1%. Surgical resection was associated with the highest success rate. Multivariate analysis showed a significant difference for surgical resection alone.
- Subjects :
- Adult
Male
Proto-Oncogene Proteins B-raf
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Multivariate analysis
next‐generation sequencing gene panel
Oncomine Dx
Clinical Research
Carcinoma, Non-Small-Cell Lung
Proto-Oncogene Proteins
Internal medicine
Biopsy
Clinical endpoint
medicine
ROS1
Humans
Anaplastic Lymphoma Kinase
Genetic Testing
Lung cancer
non‐small‐cell lung cancer
turnaround time
Aged
Retrospective Studies
Aged, 80 and over
medicine.diagnostic_test
business.industry
High-Throughput Nucleotide Sequencing
Sequence Analysis, DNA
Original Articles
General Medicine
Odds ratio
Middle Aged
Protein-Tyrosine Kinases
Prognosis
medicine.disease
ErbB Receptors
Treatment Outcome
Multivariate Analysis
Mutation
Female
Original Article
business
Real world data
Companion diagnostic
Subjects
Details
- ISSN :
- 13497006 and 13479032
- Volume :
- 113
- Database :
- OpenAIRE
- Journal :
- Cancer Science
- Accession number :
- edsair.doi.dedup.....c5f6957f9a355908e80698c7c63981f5